• Rein Therapeutics reported peer-reviewed publication of first-in-human LTI-03 data in Nature Communications; results were previously presented as a preprint in November 2025.
• The small, randomized, placebo-controlled study in idiopathic pulmonary fibrosis showed LTI-03 was safe and well-tolerated over 14 days.
• Findings indicated reductions in markers tied to lung scarring and inflammation, supporting the ongoing Phase 2 RENEW trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040800PRIMZONEFULLFEED9802980) on August 04, 2026, and is solely responsible for the information contained therein.